HDAC9 and T-cell non-Hodgkin lymphoma: For example, in a multi-institutional retrospective effort of 127 patients with R/R nodal T-cell lymphoma treated with an HDAC inhibitor, patients with a TFH phenotype had an improved ORR of 57% versus 30% in those with a non-TFH phenotype (p = 0.004) [51].